Positive results for acalabrutinib in Waldenström's macroglobulinemia

Positive results for acalabrutinib in Waldenström's macroglobulinemia

User Photo
VJHemOnc

2 years
44 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
BTK inhibition is a popular avenue of treatment research in Waldenström's macroglobulinemia (WM). In this video, recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, in Stockholm, Sweden, Simon Rule, MD, of Plymouth University, Plymouth, UK, discusses the recent trial (NCT02180724) exploring the efficacy of BTK inhibitor acalabrutinib monotherapy in both the frontline and relapsed/refractory settings. The data were overwhelmingly positive, with response rate and overall survival at 2 years both reaching >90%, and a relatively low toxicity. Finally, Prof. Rule touches upon the positive data from ibrutinib/rituximab combination therapies, and suggests that even better results might be achieved when acalabrutinib is also combined with rituximab.
Up Next Autoplay